VALENCIA.BO · BSE
Valencia Nutrition Limited
₹60
+1.69% (+₹1)
Prev. close
₹59
Volume
3,000
As of
11 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Valencia Nutrition Limited
Valencia Nutrition Limited operates as a FMCG company in India. The company offers beverages and super water, can beverages, and A2 cow dairies; consumer products, such as chabao, chocolates, perfumes, toothpastes, ease out, antacid effervescents, chewing gums and oral care, and mints; and nutracare lifesciences products, including infant food, kids, protein powder, pregnancy care, and lactation care products. It also provides snacks and health bite products; and lifestyle products. In addition, the company operates Bounce Café. Further, it is involved in the manufacturing and sale of PET-bottle beverages, including functional waters, hydration, RTD, and carbonated formats; and provision of automated retail and hospitality solutions, including vending machines, VisiCoolers, Smart Soda Fountains, hot beverage and French fries vending, and Aroma De Valencia diffusers. Valencia Nutrition Limited was incorporated in 2013 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Manish Pravinchandra Turakhia
Headquarters
Mumbai
Employees
75
Website
valencianutrition.comExchange
View on BSE ↗Key stats
Market cap
₹119.04 Cr
P/E ratio (TTM)
115.4
EPS (TTM)
₹0.52
Beta (1Y · daily vs NIFTY 50)
0.57
Beta (5Y · monthly vs NIFTY 50)
1.76
Shares float
38.30 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹1.46 Cr | ₹1.34 Cr | ₹8.47 Cr | ₹7.88 Cr | |
| EBITDA | — | ₹-1.19 Cr | ₹-1.30 Cr | ₹1.41 Cr | ₹1.87 Cr |
| — | ₹-1.26 Cr | ₹-1.38 Cr | ₹1.07 Cr | ₹1.09 Cr | |
| Diluted EPS | ₹-0.66 | ₹-2.26 | ₹-2.48 | ₹0.77 | ₹0.52 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2.78 Cr | ₹6.00 Cr | ₹38.42 Cr | ₹59.05 Cr | |
| ₹2.18 Cr | ₹5.34 Cr | ₹1.49 Cr | ₹15.13 Cr | |
| Stockholders' equity | ₹-66.61 L | ₹-2.05 Cr | ₹36.58 Cr | ₹42.19 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-1.55 Cr | ₹-75.62 L | ₹-15.73 Cr | ₹-8.19 Cr | |
| Investing cash flow | — | ₹0 | ₹-2.22 Cr | ₹-10.17 Cr | ₹-16.79 Cr |
| — | ₹1.58 Cr | ₹3.13 Cr | ₹33.57 Cr | ₹17.39 Cr | |
| Capital expenditure | — | — | ₹-2.22 Cr | ₹-4.08 Cr | ₹-20.36 Cr |
| End cash position | — | ₹7.55 L | ₹22.30 L | ₹7.90 Cr | ₹30.41 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Valencia Nutrition Limited | ₹119.04 Cr | ₹60 | 115.4 | 2.82 | 2.6% | 0.36 | -7.0% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.